Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
Identifieur interne : 004770 ( Main/Exploration ); précédent : 004769; suivant : 004771Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
Auteurs : Sagar U. Kapadia [États-Unis] ; John K. Rose ; Elaine Lamirande ; Leatrice Vogel ; Kanta Subbarao ; Anjeanette RobertsSource :
- Virology [ 0042-6822 ] ; 2005.
Descripteurs français
- KwdFr :
- Amorces ADN, Animaux, Cricetinae, Immunité cellulaire, Lignée cellulaire, Production d'anticorps, RT-PCR, Rein, Souris, Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux, Vaccins atténués, Vaccins à ADN, Virus de la stomatite vésiculeuse de type Indiana (immunologie), Virus du SRAS (génétique), Virus du SRAS (immunologie).
- MESH :
- génétique : Virus du SRAS.
- immunologie : Syndrome respiratoire aigu sévère, Virus de la stomatite vésiculeuse de type Indiana, Virus du SRAS.
- Amorces ADN, Animaux, Cricetinae, Immunité cellulaire, Lignée cellulaire, Production d'anticorps, RT-PCR, Rein, Souris, Vaccins antiviraux, Vaccins atténués, Vaccins à ADN.
English descriptors
- KwdEn :
- Animals, Antibody Formation, Cell Line, Cricetinae, DNA Primers, Immunity, Cellular, Kidney, Mice, Reverse Transcriptase Polymerase Chain Reaction, SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Vaccines, Attenuated, Vaccines, DNA, Vesicular stomatitis Indiana virus (immunology), Viral Vaccines.
- MESH :
- chemical : DNA Primers, Vaccines, Attenuated, Vaccines, DNA, Viral Vaccines.
- genetics : SARS Virus.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, Vesicular stomatitis Indiana virus.
- Animals, Antibody Formation, Cell Line, Cricetinae, Immunity, Cellular, Kidney, Mice, Reverse Transcriptase Polymerase Chain Reaction.
Abstract
Although the recent SARS coronavirus (SARS-CoV) that appeared in 2002 has now been contained, the possibility of re-emergence of SARS-CoV remains. Due to the threat of re-emergence, the overall fatality rate of approximately 10%, and the rapid dispersion of the virus via international travel, viable vaccine candidates providing protection from SARS are clearly needed. We developed an attenuated VSV recombinant (VSV-S) expressing the SARS coronavirus (SARS-CoV) spike (S) protein. In cells infected with this recombinant, S protein was synthesized, glycosylated at approximately 17 Asn residues, and transported via the Golgi to the cell surface. Mice vaccinated with VSV-S developed SARS-neutralizing antibody and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single vaccination. We also demonstrated, by passive antibody transfer, that the antibody response induced by the vaccine was sufficient for controlling SARS-CoV infection. A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date.
DOI: 10.1016/j.virol.2005.06.016
PubMed: 16043204
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002624
- to stream PubMed, to step Curation: 002624
- to stream PubMed, to step Checkpoint: 002636
- to stream Ncbi, to step Merge: 001078
- to stream Ncbi, to step Curation: 001078
- to stream Ncbi, to step Checkpoint: 001078
- to stream Main, to step Merge: 004A49
- to stream Main, to step Curation: 004770
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.</title><author><name sortKey="Kapadia, Sagar U" sort="Kapadia, Sagar U" uniqKey="Kapadia S" first="Sagar U" last="Kapadia">Sagar U. Kapadia</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Yale University School of Medicine, New Haven, CT 06510</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K" last="Rose">John K. Rose</name></author><author><name sortKey="Lamirande, Elaine" sort="Lamirande, Elaine" uniqKey="Lamirande E" first="Elaine" last="Lamirande">Elaine Lamirande</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16043204</idno><idno type="pmid">16043204</idno><idno type="doi">10.1016/j.virol.2005.06.016</idno><idno type="wicri:Area/PubMed/Corpus">002624</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002624</idno><idno type="wicri:Area/PubMed/Curation">002624</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002624</idno><idno type="wicri:Area/PubMed/Checkpoint">002636</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002636</idno><idno type="wicri:Area/Ncbi/Merge">001078</idno><idno type="wicri:Area/Ncbi/Curation">001078</idno><idno type="wicri:Area/Ncbi/Checkpoint">001078</idno><idno type="wicri:doubleKey">0042-6822:2005:Kapadia S:long:term:protection</idno><idno type="wicri:Area/Main/Merge">004A49</idno><idno type="wicri:Area/Main/Curation">004770</idno><idno type="wicri:Area/Main/Exploration">004770</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.</title><author><name sortKey="Kapadia, Sagar U" sort="Kapadia, Sagar U" uniqKey="Kapadia S" first="Sagar U" last="Kapadia">Sagar U. Kapadia</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Yale University School of Medicine, New Haven, CT 06510</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K" last="Rose">John K. Rose</name></author><author><name sortKey="Lamirande, Elaine" sort="Lamirande, Elaine" uniqKey="Lamirande E" first="Elaine" last="Lamirande">Elaine Lamirande</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></author></analytic><series><title level="j">Virology</title><idno type="ISSN">0042-6822</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibody Formation</term><term>Cell Line</term><term>Cricetinae</term><term>DNA Primers</term><term>Immunity, Cellular</term><term>Kidney</term><term>Mice</term><term>Reverse Transcriptase Polymerase Chain Reaction</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Vaccines, Attenuated</term><term>Vaccines, DNA</term><term>Vesicular stomatitis Indiana virus (immunology)</term><term>Viral Vaccines</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Amorces ADN</term><term>Animaux</term><term>Cricetinae</term><term>Immunité cellulaire</term><term>Lignée cellulaire</term><term>Production d'anticorps</term><term>RT-PCR</term><term>Rein</term><term>Souris</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins antiviraux</term><term>Vaccins atténués</term><term>Vaccins à ADN</term><term>Virus de la stomatite vésiculeuse de type Indiana (immunologie)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>DNA Primers</term><term>Vaccines, Attenuated</term><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Virus de la stomatite vésiculeuse de type Indiana</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Vesicular stomatitis Indiana virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody Formation</term><term>Cell Line</term><term>Cricetinae</term><term>Immunity, Cellular</term><term>Kidney</term><term>Mice</term><term>Reverse Transcriptase Polymerase Chain Reaction</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Amorces ADN</term><term>Animaux</term><term>Cricetinae</term><term>Immunité cellulaire</term><term>Lignée cellulaire</term><term>Production d'anticorps</term><term>RT-PCR</term><term>Rein</term><term>Souris</term><term>Vaccins antiviraux</term><term>Vaccins atténués</term><term>Vaccins à ADN</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the recent SARS coronavirus (SARS-CoV) that appeared in 2002 has now been contained, the possibility of re-emergence of SARS-CoV remains. Due to the threat of re-emergence, the overall fatality rate of approximately 10%, and the rapid dispersion of the virus via international travel, viable vaccine candidates providing protection from SARS are clearly needed. We developed an attenuated VSV recombinant (VSV-S) expressing the SARS coronavirus (SARS-CoV) spike (S) protein. In cells infected with this recombinant, S protein was synthesized, glycosylated at approximately 17 Asn residues, and transported via the Golgi to the cell surface. Mice vaccinated with VSV-S developed SARS-neutralizing antibody and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single vaccination. We also demonstrated, by passive antibody transfer, that the antibody response induced by the vaccine was sufficient for controlling SARS-CoV infection. A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Connecticut</li></region></list><tree><noCountry><name sortKey="Lamirande, Elaine" sort="Lamirande, Elaine" uniqKey="Lamirande E" first="Elaine" last="Lamirande">Elaine Lamirande</name><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K" last="Rose">John K. Rose</name><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></noCountry><country name="États-Unis"><region name="Connecticut"><name sortKey="Kapadia, Sagar U" sort="Kapadia, Sagar U" uniqKey="Kapadia S" first="Sagar U" last="Kapadia">Sagar U. Kapadia</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004770 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004770 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16043204
|texte= Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16043204" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |